Letter To the Editor: Infliximab-induced SLE-like syndrome involving the lung and pleura

Lipsky PE , van der Heijde DM , St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group . N Engl J Med 2000; 343: 1594—1602 .

Maini R. , St. Clair EW , Breedveld F. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial . Lancet 1999; 354: 1932—1939 .

Jacob CO Tumor necrosis factor-α in autoimmunity: pretty girl or old witch? Immunol Today 1992; 13: 122—125 .

Day R. Commentary: adverse reactions to TNF-α inhibitors in rheumatoid arthritis . Lancet 2002; 359: 540—541 .

Bongartz T. , Sutton AJ , Sweeting MJ , Buchan I. , Matteson EL , Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies . JAMA 2006; 295: 2275—2285 .

Keane J. , Gershon S. , Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent . N Engl J Med 2001; 345: 1098—1104 .

Gomez-Reino JJ , Carmona L. , Valverde VR, Martin Mola E, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk . Arthritis Rheum 2003; 48: 2122—2127 .

Charles PJ , Smeenk Rjt , Dejong J. , Feldman M. , Maini RN Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in an open-label and randomized placebo-controlled trial . Arthritis Rheum 2000; 43: 2383—2390 .

De Rycke L. , Baeten D. , Kruithof E. , Van den Bosch F. , Veys FM , De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity . Arthritis Rheum 2005; 52: 2192—2201 .

DeBandt M. , Sibilia J. , Le Loet X. et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey . Arthritis Res Ther 2005; 7: 545—551 .

Good JT , King TE , Antony VB , Sahn SA Lupus Pleuritis: clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies . Chest 1983; 84: 714—718 .

Naylor B. Cytological aspects of pleural, peritoneal and pericardial fluids from patients with systemic lupus erythematosus . Cytopathology 1992; 3: 1—8 .

Aringer M. , Smolen JS Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus . Arthritis Res Ther 2003; 5: 172—177 .

Charles PJ Defective waste disposal: does it induce autoantibodies in SLE? Ann Rheum Dis 2003; 62: 1—3 .

Guo H. , Leung CK , Chan Lyy , Chan TM , Lai KN The pathogenetic role of immunoglobulin G from patients with system lupus erythematosus in the development of lupus pleuritis . Rheumatology 2004; 43: 286—293 .